Iovance Biotherapeutics, Inc. Common Stock
IOVA Real Time Price USDRecent trades of IOVA by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in IOVA holdings by institutional investors
Quarterly net insider trading by IOVA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$260,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
-
$260,000 Oct 11, 2022 Issue: Medicare/Medicaid Health Issues
-
$260,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$50,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$50,000 Apr 19, 2022 Issue: Health Issues
-
$50,000 Jan 20, 2022 Issue: Health Issues
-
$50,000 Jan 19, 2022 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2021 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2021 Issue: Health Issues
-
$50,000 Jul 20, 2021 Issue: Medicare/Medicaid
-
$50,000 Jul 19, 2021 Issue: Health Issues
-
$40,000 Apr 20, 2021 Issue: Medicare/Medicaid
-
$40,000 Apr 19, 2021 Issue: Health Issues
-
$30,000 Jan 21, 2021 Issue: Medicare/Medicaid
-
$30,000 Jan 19, 2021 Issue: Health Issues
Former government officials who have lobbied for IOVA
4 former government officials from 4 congressional offices at 3 lobbying firms have lobbied for IOVA, most recently Mar 14, 2023.
-
Nicolas Magallanes House Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander -
Tracy Spicer Senate New Deputy Chief of Staff, Political Director, Legislative Assistant, Special Assistant, Staff Assistant - Sen. Edward Kennedy -
Elizabeth Barnett Senate New Legislative Assistant, Speechwriter, Legislative Correspondent - Sen. Blanche Lincoln; Staff Assistant - Senate Energy and Natural Resources Committee -
Darren Willcox House New ​Asst. for Policy, Speaker Dennis Hastert; Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss; House Rules Comm. Assoc., Subcommittee Staff Director
IOVA Estimated quarterly lobbying spending
IOVA Revenue by Segment or Geography
New IOVA patent grants
-
Patent Title: Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors Jul. 14, 2026
-
Patent Title: Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion Jul. 07, 2026
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jun. 16, 2026
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jun. 09, 2026
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jun. 02, 2026
-
Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jun. 02, 2026
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 26, 2026
-
Patent Title: Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof May. 19, 2026
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 12, 2026
-
Patent Title: Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy Apr. 28, 2026
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 28, 2026
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 28, 2026
-
Patent Title: Treatment of nsclc patients refractory for anti-pd-1 antibody Apr. 28, 2026
-
Patent Title: Methods and compositions for t-cell coculture potency assays and use with cell therapy products Mar. 10, 2026
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 10, 2026
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 24, 2026
-
Patent Title: Methods and compositions for t-cell coculture potency assays and use with cell therapy products Feb. 17, 2026
-
Patent Title: Treatment of nsclc patients with tumor infiltrating lymphocyte therapies Feb. 17, 2026
-
Patent Title: Identification of clonal neoantigens and uses thereof Feb. 10, 2026
-
Patent Title: Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same Jan. 06, 2026
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 02, 2025
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Nov. 18, 2025
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy Oct. 28, 2025
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy Apr. 22, 2025
-
Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Feb. 25, 2025
-
Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Feb. 18, 2025
-
Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Feb. 18, 2025
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 18, 2025
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 14, 2025
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 07, 2025
-
Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Dec. 17, 2024
-
Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Dec. 03, 2024
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Oct. 22, 2024
-
Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Oct. 01, 2024
-
Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 09, 2024
-
Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 02, 2024
-
Patent Title: Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof Jul. 02, 2024
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jun. 04, 2024
-
Patent Title: Til expansion processes using specific cytokine combinations and/or akti treatment May. 14, 2024
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 07, 2024
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 30, 2024
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 26, 2024
-
Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 09, 2024
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 09, 2024
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 02, 2024
-
Patent Title: Methods of using tumor infiltrating lymphocytes in double-refractory melanoma Nov. 21, 2023
-
Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Aug. 01, 2023
-
Patent Title: Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion Jun. 06, 2023
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 16, 2023
-
Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Apr. 18, 2023
Federal grants, loans, and purchases
Estimated quarterly amount awarded to IOVA from public contracts
Recent insights relating to IOVA
Recent picks made for IOVA stock on CNBC
ETFs with the largest estimated holdings in IOVA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $IOVA stock a Buy, Sell, or Hold?
- What is the price target for $IOVA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $IOVA stock?
- Who owns the most shares of $IOVA stock?
- What funds own $IOVA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IOVA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
- Address San Carlos, CA
- Market Cap 4.8 billion
- Employees 975
- Industrial Classification Biological Products, (No Diagnostic Substances)
Iovance Biotherapeutics, Inc. Common Stock (IOVA) Historical Stock Prices
Iovance Biotherapeutics, Inc. Common Stock (IOVA) closed at $10.64 on September 22, 2026. Over the past year its adjusted close ranged from $1.81 to $10.64. Daily prices go back to June 28, 2017, 2,321 trading days in all.
- 1 month+28.35%
- 3 months+139.64%
- Year to date+289.74%
- 1 year+401.89%
- 3 years+118.48%
- 5 years-58.44%
- Max+49.86%
Quiver Premium charts IOVA's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | 10.18 | 10.80 | 10.03 | 10.64 | 10.64 | 16,058,202 |
| Sep 21, 2026 | 10.43 | 10.64 | 10.03 | 10.19 | 10.19 | 13,129,488 |
| Sep 18, 2026 | 10.12 | 10.27 | 9.83 | 10.25 | 10.25 | 22,879,704 |
| Sep 17, 2026 | 10.25 | 10.98 | 9.98 | 10.02 | 10.02 | 24,203,830 |
| Sep 16, 2026 | 9.45 | 9.93 | 9.44 | 9.87 | 9.87 | 19,693,852 |
| Sep 15, 2026 | 9.21 | 9.38 | 8.98 | 9.36 | 9.36 | 11,092,032 |
| Sep 14, 2026 | 8.56 | 9.41 | 8.54 | 9.26 | 9.26 | 21,037,139 |
| Sep 11, 2026 | 8.25 | 8.70 | 8.07 | 8.60 | 8.60 | 12,388,719 |
| Sep 10, 2026 | 8.32 | 8.42 | 8.04 | 8.14 | 8.14 | 10,570,381 |
| Sep 9, 2026 | 8.65 | 8.73 | 8.32 | 8.43 | 8.43 | 11,938,869 |
| Sep 8, 2026 | 8.69 | 8.91 | 8.48 | 8.70 | 8.70 | 9,543,182 |
| Sep 4, 2026 | 8.74 | 8.90 | 8.63 | 8.79 | 8.79 | 8,079,575 |
| Sep 3, 2026 | 8.65 | 8.79 | 8.55 | 8.70 | 8.70 | 14,637,233 |
| Sep 2, 2026 | 8.31 | 8.69 | 8.29 | 8.62 | 8.62 | 12,393,157 |
| Sep 1, 2026 | 8.02 | 8.29 | 7.97 | 8.28 | 8.28 | 6,760,744 |
| Aug 31, 2026 | 7.95 | 8.17 | 7.66 | 8.17 | 8.17 | 12,126,275 |
| Aug 28, 2026 | 8.20 | 8.35 | 7.97 | 8.01 | 8.01 | 7,693,530 |
| Aug 27, 2026 | 8.08 | 8.32 | 7.95 | 8.26 | 8.26 | 7,437,094 |
| Aug 26, 2026 | 8.34 | 8.55 | 8.02 | 8.08 | 8.08 | 10,102,348 |
| Aug 25, 2026 | 8.16 | 8.48 | 8.03 | 8.44 | 8.44 | 11,907,843 |
| Aug 24, 2026 | 8.08 | 8.36 | 7.79 | 8.06 | 8.06 | 15,731,204 |
| Aug 21, 2026 | 9.08 | 9.30 | 8.14 | 8.29 | 8.29 | 27,808,868 |
| Aug 20, 2026 | 8.07 | 9.36 | 7.96 | 8.99 | 8.99 | 43,812,294 |
| Aug 19, 2026 | 7.20 | 8.05 | 7.19 | 7.99 | 7.99 | 24,248,267 |
| Aug 18, 2026 | 7.00 | 7.31 | 6.93 | 7.03 | 7.03 | 10,499,437 |
| Aug 17, 2026 | 6.84 | 7.25 | 6.70 | 7.10 | 7.10 | 14,811,114 |
| Aug 14, 2026 | 6.52 | 7.00 | 6.36 | 6.98 | 6.98 | 17,507,568 |
| Aug 13, 2026 | 6.74 | 6.81 | 6.42 | 6.52 | 6.52 | 15,679,356 |
| Aug 12, 2026 | 6.49 | 6.74 | 6.39 | 6.74 | 6.74 | 13,458,733 |
| Aug 11, 2026 | 6.48 | 6.53 | 6.18 | 6.49 | 6.49 | 10,381,001 |
| Aug 10, 2026 | 6.31 | 6.61 | 6.16 | 6.40 | 6.40 | 17,306,205 |
| Aug 7, 2026 | 6.57 | 6.92 | 5.88 | 6.34 | 6.34 | 30,970,676 |
| Aug 6, 2026 | 5.95 | 6.39 | 5.63 | 6.21 | 6.21 | 73,430,649 |
| Aug 5, 2026 | 4.45 | 4.55 | 4.29 | 4.34 | 4.34 | 15,595,197 |
| Aug 4, 2026 | 4.39 | 4.48 | 4.29 | 4.36 | 4.36 | 10,682,083 |
| Aug 3, 2026 | 4.10 | 4.36 | 3.96 | 4.32 | 4.32 | 13,022,194 |
| Jul 31, 2026 | 4.43 | 4.55 | 4.02 | 4.07 | 4.07 | 19,974,537 |
| Jul 30, 2026 | 4.53 | 4.84 | 4.51 | 4.69 | 4.69 | 14,156,410 |
| Jul 29, 2026 | 4.73 | 4.78 | 4.50 | 4.56 | 4.56 | 10,794,369 |
| Jul 28, 2026 | 4.98 | 4.98 | 4.64 | 4.70 | 4.70 | 13,441,678 |
| Jul 27, 2026 | 5.02 | 5.16 | 4.86 | 4.90 | 4.90 | 13,245,331 |
| Jul 24, 2026 | 5.12 | 5.15 | 4.95 | 4.99 | 4.99 | 9,431,084 |
| Jul 23, 2026 | 5.03 | 5.28 | 5.00 | 5.13 | 5.13 | 9,732,094 |
| Jul 22, 2026 | 5.50 | 5.64 | 5.10 | 5.17 | 5.17 | 14,161,009 |
| Jul 21, 2026 | 5.07 | 5.53 | 5.02 | 5.48 | 5.48 | 20,354,160 |
| Jul 20, 2026 | 5.03 | 5.13 | 4.80 | 5.02 | 5.02 | 16,361,516 |
| Jul 17, 2026 | 4.54 | 5.07 | 4.44 | 5.00 | 5.00 | 23,478,578 |
| Jul 16, 2026 | 4.62 | 5.13 | 4.60 | 4.66 | 4.66 | 28,210,344 |
| Jul 15, 2026 | 3.92 | 4.80 | 3.76 | 4.74 | 4.74 | 43,697,871 |
| Jul 14, 2026 | 4.06 | 4.07 | 3.90 | 3.93 | 3.93 | 13,351,020 |
| Jul 13, 2026 | 4.16 | 4.17 | 4.00 | 4.04 | 4.04 | 13,326,232 |
| Jul 10, 2026 | 4.41 | 4.45 | 4.14 | 4.23 | 4.23 | 9,924,816 |
| Jul 9, 2026 | 4.30 | 4.53 | 4.28 | 4.37 | 4.37 | 13,730,301 |
| Jul 8, 2026 | 4.33 | 4.48 | 4.19 | 4.28 | 4.28 | 10,335,109 |
| Jul 7, 2026 | 4.25 | 4.41 | 4.07 | 4.35 | 4.35 | 11,634,878 |
| Jul 6, 2026 | 4.30 | 4.54 | 4.18 | 4.19 | 4.19 | 12,775,710 |
| Jul 2, 2026 | 4.07 | 4.32 | 3.89 | 4.31 | 4.31 | 20,542,153 |
| Jul 1, 2026 | 4.16 | 4.29 | 3.85 | 3.97 | 3.97 | 21,395,779 |
| Jun 30, 2026 | 4.23 | 4.33 | 4.14 | 4.16 | 4.16 | 10,252,161 |
| Jun 29, 2026 | 4.33 | 4.46 | 4.17 | 4.21 | 4.21 | 10,660,230 |
| Jun 26, 2026 | 4.21 | 4.41 | 4.12 | 4.25 | 4.25 | 23,715,866 |
| Jun 25, 2026 | 4.26 | 4.34 | 4.14 | 4.21 | 4.21 | 9,005,609 |
| Jun 24, 2026 | 4.55 | 4.76 | 4.22 | 4.25 | 4.25 | 15,618,985 |
| Jun 23, 2026 | 4.00 | 4.52 | 3.99 | 4.44 | 4.44 | 17,975,949 |
| Jun 22, 2026 | 3.92 | 4.20 | 3.91 | 4.06 | 4.06 | 11,624,401 |
| Jun 18, 2026 | 3.97 | 4.05 | 3.85 | 3.91 | 3.91 | 23,714,726 |
| Jun 17, 2026 | 3.88 | 4.12 | 3.81 | 3.93 | 3.93 | 11,208,025 |
| Jun 16, 2026 | 4.07 | 4.12 | 3.80 | 3.82 | 3.82 | 9,003,991 |
| Jun 15, 2026 | 4.12 | 4.15 | 3.89 | 4.03 | 4.03 | 12,659,269 |
| Jun 12, 2026 | 3.95 | 4.23 | 3.95 | 4.08 | 4.08 | 10,969,941 |
| Jun 11, 2026 | 3.77 | 4.02 | 3.70 | 3.96 | 3.96 | 11,510,947 |
| Jun 10, 2026 | 3.85 | 4.06 | 3.76 | 3.78 | 3.78 | 8,880,518 |
| Jun 9, 2026 | 4.09 | 4.13 | 3.77 | 3.88 | 3.88 | 11,270,614 |
| Jun 8, 2026 | 4.29 | 4.35 | 3.98 | 4.00 | 4.00 | 11,287,481 |
| Jun 5, 2026 | 4.50 | 4.56 | 4.17 | 4.23 | 4.23 | 19,690,915 |
| Jun 4, 2026 | 3.85 | 4.58 | 3.85 | 4.38 | 4.38 | 22,604,329 |
| Jun 3, 2026 | 4.10 | 4.12 | 3.77 | 3.79 | 3.79 | 9,667,593 |
| Jun 2, 2026 | 3.91 | 4.17 | 3.90 | 4.10 | 4.10 | 12,715,770 |
| Jun 1, 2026 | 4.11 | 4.20 | 3.90 | 3.96 | 3.96 | 14,458,960 |
| May 29, 2026 | 4.18 | 4.23 | 3.88 | 4.10 | 4.10 | 17,279,249 |
| May 28, 2026 | 4.38 | 4.51 | 4.27 | 4.30 | 4.30 | 9,265,953 |
| May 27, 2026 | 4.08 | 4.49 | 4.04 | 4.37 | 4.37 | 12,819,903 |
| May 26, 2026 | 4.08 | 4.25 | 3.95 | 4.10 | 4.10 | 14,580,816 |
| May 22, 2026 | 3.70 | 4.20 | 3.69 | 4.11 | 4.11 | 23,101,121 |
| May 21, 2026 | 3.54 | 3.72 | 3.46 | 3.70 | 3.70 | 10,607,701 |
| May 20, 2026 | 3.48 | 3.65 | 3.48 | 3.54 | 3.54 | 8,937,099 |
| May 19, 2026 | 3.38 | 3.50 | 3.28 | 3.46 | 3.46 | 8,589,442 |
| May 18, 2026 | 3.51 | 3.57 | 3.35 | 3.39 | 3.39 | 10,237,083 |
| May 15, 2026 | 3.46 | 3.50 | 3.41 | 3.45 | 3.45 | 7,853,227 |
| May 14, 2026 | 3.65 | 3.74 | 3.48 | 3.52 | 3.52 | 12,614,581 |
| May 13, 2026 | 3.56 | 3.71 | 3.51 | 3.66 | 3.66 | 7,883,682 |
| May 12, 2026 | 3.74 | 3.74 | 3.51 | 3.56 | 3.56 | 20,988,916 |
| May 11, 2026 | 3.64 | 4.03 | 3.64 | 3.70 | 3.70 | 19,047,401 |
| May 8, 2026 | 3.52 | 3.62 | 3.38 | 3.62 | 3.62 | 20,688,669 |
| May 7, 2026 | 3.51 | 4.08 | 3.46 | 3.55 | 3.55 | 40,972,368 |
| May 6, 2026 | 3.99 | 4.15 | 3.91 | 4.09 | 4.09 | 17,051,772 |
| May 5, 2026 | 3.82 | 4.00 | 3.80 | 3.98 | 3.98 | 18,350,287 |
| May 4, 2026 | 3.44 | 3.88 | 3.41 | 3.85 | 3.85 | 22,610,294 |
| May 1, 2026 | 3.37 | 3.50 | 3.34 | 3.40 | 3.40 | 9,933,825 |
| Apr 30, 2026 | 3.34 | 3.42 | 3.30 | 3.36 | 3.36 | 16,314,671 |
| Apr 29, 2026 | 3.37 | 3.37 | 3.27 | 3.31 | 3.31 | 8,938,445 |
| Apr 28, 2026 | 3.43 | 3.50 | 3.33 | 3.38 | 3.38 | 11,297,312 |
| Apr 27, 2026 | 3.45 | 3.58 | 3.42 | 3.43 | 3.43 | 10,322,755 |
| Apr 24, 2026 | 3.49 | 3.57 | 3.40 | 3.44 | 3.44 | 11,715,211 |
| Apr 23, 2026 | 3.50 | 3.58 | 3.38 | 3.48 | 3.48 | 15,322,918 |
| Apr 22, 2026 | 3.75 | 3.81 | 3.40 | 3.53 | 3.53 | 22,203,968 |
| Apr 21, 2026 | 3.79 | 3.91 | 3.65 | 3.70 | 3.70 | 10,956,783 |
| Apr 20, 2026 | 3.75 | 3.86 | 3.66 | 3.78 | 3.78 | 9,751,117 |
| Apr 17, 2026 | 3.93 | 3.97 | 3.85 | 3.86 | 3.86 | 10,684,185 |
| Apr 16, 2026 | 3.82 | 3.87 | 3.71 | 3.80 | 3.80 | 11,014,677 |
| Apr 15, 2026 | 3.68 | 3.83 | 3.53 | 3.82 | 3.82 | 12,235,417 |
| Apr 14, 2026 | 3.49 | 3.69 | 3.44 | 3.64 | 3.64 | 13,922,189 |
| Apr 13, 2026 | 3.69 | 3.81 | 3.42 | 3.46 | 3.46 | 17,946,613 |
| Apr 10, 2026 | 3.99 | 4.31 | 3.62 | 3.70 | 3.70 | 44,592,905 |
| Apr 9, 2026 | 3.49 | 4.05 | 3.48 | 4.01 | 4.01 | 26,733,346 |
| Apr 8, 2026 | 3.46 | 3.50 | 3.25 | 3.47 | 3.47 | 15,629,660 |
| Apr 7, 2026 | 3.26 | 3.43 | 3.18 | 3.32 | 3.32 | 9,710,655 |
| Apr 6, 2026 | 3.42 | 3.48 | 3.28 | 3.30 | 3.30 | 9,803,818 |
| Apr 2, 2026 | 3.33 | 3.50 | 3.32 | 3.43 | 3.43 | 7,803,480 |
| Apr 1, 2026 | 3.60 | 3.65 | 3.39 | 3.45 | 3.45 | 9,268,499 |
| Mar 31, 2026 | 3.43 | 3.58 | 3.37 | 3.51 | 3.51 | 10,974,150 |
| Mar 30, 2026 | 3.51 | 3.51 | 3.26 | 3.32 | 3.32 | 9,934,944 |
| Mar 27, 2026 | 3.66 | 3.71 | 3.51 | 3.51 | 3.51 | 8,496,946 |
| Mar 26, 2026 | 3.58 | 3.81 | 3.52 | 3.69 | 3.69 | 7,473,340 |
| Mar 25, 2026 | 3.73 | 3.97 | 3.69 | 3.75 | 3.75 | 10,577,447 |
| Mar 24, 2026 | 3.60 | 3.68 | 3.43 | 3.62 | 3.62 | 11,852,086 |
| Mar 23, 2026 | 3.73 | 3.81 | 3.62 | 3.63 | 3.63 | 9,005,781 |
| Mar 20, 2026 | 3.87 | 3.96 | 3.61 | 3.69 | 3.69 | 23,502,040 |
| Mar 19, 2026 | 3.71 | 3.89 | 3.61 | 3.87 | 3.87 | 10,477,127 |
| Mar 18, 2026 | 3.81 | 4.03 | 3.76 | 3.77 | 3.77 | 14,468,851 |
| Mar 17, 2026 | 4.02 | 4.12 | 3.83 | 3.89 | 3.89 | 9,749,682 |
| Mar 16, 2026 | 3.99 | 4.14 | 3.91 | 4.04 | 4.04 | 14,697,790 |
| Mar 13, 2026 | 4.20 | 4.21 | 3.81 | 3.96 | 3.96 | 19,365,566 |
| Mar 12, 2026 | 4.66 | 4.74 | 4.01 | 4.07 | 4.07 | 26,434,416 |
| Mar 11, 2026 | 5.20 | 5.36 | 4.78 | 4.84 | 4.84 | 20,821,442 |
| Mar 10, 2026 | 5.42 | 5.42 | 5.09 | 5.20 | 5.20 | 19,787,867 |
| Mar 9, 2026 | 5.02 | 5.63 | 5.01 | 5.41 | 5.41 | 27,551,172 |
| Mar 6, 2026 | 4.42 | 5.35 | 4.38 | 5.13 | 5.13 | 44,562,758 |
| Mar 5, 2026 | 4.21 | 4.60 | 4.11 | 4.58 | 4.58 | 23,716,766 |
| Mar 4, 2026 | 3.80 | 4.28 | 3.73 | 4.26 | 4.26 | 24,679,124 |
| Mar 3, 2026 | 3.62 | 3.95 | 3.57 | 3.75 | 3.75 | 13,973,806 |
| Mar 2, 2026 | 3.67 | 3.90 | 3.67 | 3.79 | 3.79 | 12,998,054 |
| Feb 27, 2026 | 3.79 | 3.90 | 3.65 | 3.86 | 3.86 | 19,051,939 |
| Feb 26, 2026 | 3.82 | 3.84 | 3.50 | 3.79 | 3.79 | 22,467,361 |
| Feb 25, 2026 | 4.17 | 4.35 | 3.78 | 3.83 | 3.83 | 46,176,839 |
| Feb 24, 2026 | 3.29 | 3.90 | 3.21 | 3.78 | 3.78 | 69,670,042 |
| Feb 23, 2026 | 2.87 | 2.99 | 2.81 | 2.89 | 2.89 | 11,985,104 |
| Feb 20, 2026 | 2.83 | 2.89 | 2.75 | 2.87 | 2.87 | 9,186,959 |
| Feb 19, 2026 | 2.72 | 2.87 | 2.68 | 2.85 | 2.85 | 8,701,712 |
| Feb 18, 2026 | 2.62 | 2.76 | 2.60 | 2.72 | 2.72 | 7,065,750 |
| Feb 17, 2026 | 2.55 | 2.64 | 2.46 | 2.62 | 2.62 | 6,628,383 |
| Feb 13, 2026 | 2.57 | 2.65 | 2.54 | 2.57 | 2.57 | 6,428,560 |
| Feb 12, 2026 | 2.66 | 2.68 | 2.50 | 2.52 | 2.52 | 5,818,480 |
| Feb 11, 2026 | 2.58 | 2.60 | 2.48 | 2.60 | 2.60 | 6,954,903 |
| Feb 10, 2026 | 2.61 | 2.73 | 2.57 | 2.60 | 2.60 | 8,500,471 |
| Feb 9, 2026 | 2.52 | 2.61 | 2.46 | 2.60 | 2.60 | 6,924,712 |
| Feb 6, 2026 | 2.42 | 2.58 | 2.42 | 2.53 | 2.53 | 6,916,224 |
| Feb 5, 2026 | 2.40 | 2.46 | 2.25 | 2.36 | 2.36 | 15,771,876 |
| Feb 4, 2026 | 2.65 | 2.71 | 2.43 | 2.44 | 2.44 | 12,260,548 |
| Feb 3, 2026 | 2.62 | 2.77 | 2.57 | 2.64 | 2.64 | 9,993,256 |
| Feb 2, 2026 | 2.56 | 2.66 | 2.47 | 2.61 | 2.61 | 11,097,041 |
| Jan 30, 2026 | 2.60 | 2.68 | 2.53 | 2.55 | 2.55 | 9,051,778 |
| Jan 29, 2026 | 2.75 | 2.84 | 2.62 | 2.63 | 2.63 | 10,709,437 |
| Jan 28, 2026 | 2.99 | 3.03 | 2.73 | 2.75 | 2.75 | 11,354,146 |
| Jan 27, 2026 | 2.87 | 3.01 | 2.87 | 2.98 | 2.98 | 15,584,249 |
| Jan 26, 2026 | 2.64 | 2.97 | 2.57 | 2.89 | 2.89 | 18,081,117 |
| Jan 23, 2026 | 2.67 | 2.69 | 2.52 | 2.64 | 2.64 | 12,112,427 |
| Jan 22, 2026 | 2.52 | 2.72 | 2.49 | 2.69 | 2.69 | 13,736,231 |
| Jan 21, 2026 | 2.45 | 2.57 | 2.42 | 2.51 | 2.51 | 12,059,016 |
| Jan 20, 2026 | 2.26 | 2.56 | 2.24 | 2.44 | 2.44 | 14,029,042 |
| Jan 16, 2026 | 2.24 | 2.41 | 2.23 | 2.36 | 2.36 | 23,435,207 |
| Jan 15, 2026 | 2.37 | 2.37 | 2.21 | 2.22 | 2.22 | 14,317,598 |
| Jan 14, 2026 | 2.35 | 2.40 | 2.33 | 2.38 | 2.38 | 7,582,996 |
| Jan 13, 2026 | 2.41 | 2.42 | 2.29 | 2.35 | 2.35 | 10,660,120 |
| Jan 12, 2026 | 2.48 | 2.48 | 2.35 | 2.40 | 2.40 | 11,478,696 |
| Jan 9, 2026 | 2.65 | 2.72 | 2.44 | 2.45 | 2.45 | 9,854,971 |
| Jan 8, 2026 | 2.75 | 2.75 | 2.56 | 2.61 | 2.61 | 10,764,654 |
| Jan 7, 2026 | 2.61 | 2.80 | 2.59 | 2.77 | 2.77 | 13,732,402 |
| Jan 6, 2026 | 2.41 | 2.65 | 2.41 | 2.55 | 2.55 | 8,880,181 |
| Jan 5, 2026 | 2.52 | 2.57 | 2.41 | 2.45 | 2.45 | 14,074,020 |
| Jan 2, 2026 | 2.78 | 2.82 | 2.50 | 2.52 | 2.52 | 15,149,662 |
| Dec 31, 2025 | 2.71 | 2.83 | 2.69 | 2.73 | 2.73 | 11,176,143 |
| Dec 30, 2025 | 2.78 | 2.88 | 2.74 | 2.77 | 2.77 | 9,013,292 |
| Dec 29, 2025 | 2.86 | 2.86 | 2.69 | 2.79 | 2.79 | 8,868,007 |
| Dec 26, 2025 | 2.92 | 2.99 | 2.82 | 2.85 | 2.85 | 8,113,431 |
| Dec 24, 2025 | 2.83 | 2.95 | 2.83 | 2.87 | 2.87 | 7,684,523 |
| Dec 23, 2025 | 2.81 | 2.83 | 2.69 | 2.82 | 2.82 | 12,025,064 |
| Dec 22, 2025 | 2.48 | 2.78 | 2.47 | 2.78 | 2.78 | 14,217,883 |
| Dec 19, 2025 | 2.49 | 2.58 | 2.40 | 2.48 | 2.48 | 29,951,805 |
| Dec 18, 2025 | 2.58 | 2.60 | 2.39 | 2.46 | 2.46 | 10,260,738 |
| Dec 17, 2025 | 2.26 | 2.57 | 2.26 | 2.52 | 2.52 | 23,272,128 |
| Dec 16, 2025 | 2.15 | 2.32 | 2.08 | 2.25 | 2.25 | 14,161,234 |
| Dec 15, 2025 | 2.24 | 2.24 | 2.13 | 2.16 | 2.16 | 9,475,523 |
| Dec 12, 2025 | 2.24 | 2.26 | 2.17 | 2.20 | 2.20 | 10,617,607 |
| Dec 11, 2025 | 2.26 | 2.32 | 2.24 | 2.25 | 2.25 | 13,860,410 |
| Dec 10, 2025 | 2.23 | 2.29 | 2.17 | 2.26 | 2.26 | 7,328,207 |
| Dec 9, 2025 | 2.29 | 2.33 | 2.24 | 2.25 | 2.25 | 7,043,563 |
| Dec 8, 2025 | 2.20 | 2.34 | 2.16 | 2.31 | 2.31 | 14,076,620 |
| Dec 5, 2025 | 2.20 | 2.25 | 2.17 | 2.20 | 2.20 | 6,622,490 |
| Dec 4, 2025 | 2.20 | 2.24 | 2.16 | 2.20 | 2.20 | 8,746,922 |
| Dec 3, 2025 | 2.14 | 2.23 | 2.14 | 2.21 | 2.21 | 7,854,285 |
| Dec 2, 2025 | 2.26 | 2.27 | 2.13 | 2.13 | 2.13 | 7,760,343 |
| Dec 1, 2025 | 2.42 | 2.42 | 2.22 | 2.23 | 2.23 | 11,802,711 |
| Nov 28, 2025 | 2.44 | 2.48 | 2.40 | 2.47 | 2.47 | 3,445,699 |
| Nov 26, 2025 | 2.48 | 2.50 | 2.41 | 2.44 | 2.44 | 6,730,192 |
| Nov 25, 2025 | 2.53 | 2.54 | 2.41 | 2.48 | 2.48 | 9,522,155 |
| Nov 24, 2025 | 2.28 | 2.54 | 2.25 | 2.50 | 2.50 | 16,014,534 |
| Nov 21, 2025 | 2.16 | 2.25 | 2.09 | 2.24 | 2.24 | 8,081,841 |
| Nov 20, 2025 | 2.29 | 2.36 | 2.16 | 2.18 | 2.18 | 8,555,202 |
| Nov 19, 2025 | 2.44 | 2.44 | 2.22 | 2.26 | 2.26 | 9,943,788 |
| Nov 18, 2025 | 2.40 | 2.62 | 2.36 | 2.44 | 2.44 | 10,977,813 |
| Nov 17, 2025 | 2.48 | 2.54 | 2.36 | 2.42 | 2.42 | 17,825,890 |
| Nov 14, 2025 | 2.35 | 2.52 | 2.34 | 2.47 | 2.47 | 16,042,418 |
| Nov 13, 2025 | 2.52 | 2.56 | 2.41 | 2.41 | 2.41 | 11,331,147 |
| Nov 12, 2025 | 2.64 | 2.72 | 2.47 | 2.54 | 2.54 | 14,759,814 |
| Nov 11, 2025 | 2.41 | 2.74 | 2.35 | 2.65 | 2.65 | 26,850,047 |
| Nov 10, 2025 | 2.42 | 2.60 | 2.35 | 2.37 | 2.37 | 24,145,070 |
| Nov 7, 2025 | 2.25 | 2.38 | 2.08 | 2.30 | 2.30 | 29,618,692 |
| Nov 6, 2025 | 2.26 | 2.51 | 2.10 | 2.31 | 2.31 | 83,726,609 |
| Nov 5, 2025 | 1.83 | 1.87 | 1.76 | 1.81 | 1.81 | 17,711,674 |
| Nov 4, 2025 | 1.88 | 1.93 | 1.80 | 1.82 | 1.82 | 16,092,595 |
| Nov 3, 2025 | 2.15 | 2.20 | 1.85 | 1.95 | 1.95 | 50,971,627 |
| Oct 31, 2025 | 1.97 | 2.00 | 1.94 | 1.97 | 1.97 | 10,872,025 |
| Oct 30, 2025 | 1.99 | 2.07 | 1.93 | 1.95 | 1.95 | 12,532,517 |
| Oct 29, 2025 | 2.16 | 2.17 | 2.00 | 2.00 | 2.00 | 24,478,047 |
| Oct 28, 2025 | 2.31 | 2.35 | 2.16 | 2.19 | 2.19 | 10,161,099 |
| Oct 27, 2025 | 2.27 | 2.34 | 2.25 | 2.31 | 2.31 | 9,685,567 |
| Oct 24, 2025 | 2.23 | 2.26 | 2.16 | 2.25 | 2.25 | 9,293,649 |
| Oct 23, 2025 | 2.15 | 2.22 | 2.12 | 2.19 | 2.19 | 7,637,657 |
| Oct 22, 2025 | 2.25 | 2.25 | 2.10 | 2.15 | 2.15 | 13,741,722 |
| Oct 21, 2025 | 2.29 | 2.34 | 2.21 | 2.27 | 2.27 | 14,985,623 |
| Oct 20, 2025 | 2.23 | 2.41 | 2.23 | 2.32 | 2.32 | 20,957,757 |
| Oct 17, 2025 | 2.19 | 2.24 | 2.13 | 2.18 | 2.18 | 9,271,963 |
| Oct 16, 2025 | 2.26 | 2.31 | 2.20 | 2.24 | 2.24 | 11,558,510 |
| Oct 15, 2025 | 2.14 | 2.27 | 2.12 | 2.24 | 2.24 | 14,330,678 |
| Oct 14, 2025 | 2.09 | 2.19 | 2.09 | 2.12 | 2.12 | 10,407,189 |
| Oct 13, 2025 | 2.15 | 2.16 | 2.09 | 2.14 | 2.14 | 8,131,141 |
| Oct 10, 2025 | 2.19 | 2.19 | 2.04 | 2.10 | 2.10 | 14,271,055 |
| Oct 9, 2025 | 2.27 | 2.28 | 2.18 | 2.19 | 2.19 | 10,977,059 |
| Oct 8, 2025 | 2.20 | 2.34 | 2.18 | 2.27 | 2.27 | 15,178,177 |
| Oct 7, 2025 | 2.21 | 2.23 | 2.09 | 2.18 | 2.18 | 11,909,068 |
| Oct 6, 2025 | 2.37 | 2.38 | 2.20 | 2.21 | 2.21 | 15,705,087 |
| Oct 3, 2025 | 2.26 | 2.35 | 2.25 | 2.34 | 2.34 | 8,740,811 |
| Oct 2, 2025 | 2.22 | 2.28 | 2.16 | 2.25 | 2.25 | 9,156,335 |
| Oct 1, 2025 | 2.16 | 2.28 | 2.16 | 2.21 | 2.21 | 6,777,785 |
| Sep 30, 2025 | 2.24 | 2.25 | 2.15 | 2.17 | 2.17 | 6,608,250 |
| Sep 29, 2025 | 2.14 | 2.25 | 2.08 | 2.23 | 2.23 | 9,535,201 |
| Sep 26, 2025 | 2.04 | 2.11 | 1.98 | 2.11 | 2.11 | 10,181,046 |
| Sep 25, 2025 | 2.08 | 2.08 | 1.97 | 2.02 | 2.02 | 10,010,442 |
| Sep 24, 2025 | 2.08 | 2.14 | 2.06 | 2.12 | 2.12 | 7,104,331 |
| Sep 23, 2025 | 2.11 | 2.17 | 2.06 | 2.07 | 2.07 | 7,204,777 |
| Sep 22, 2025 | 2.08 | 2.16 | 2.03 | 2.12 | 2.12 | 9,147,718 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at IOVA, per a recent SEC DEF 14A filing. We estimate that the median employee at IOVANCE BIOTHERAPEUTICS, INC. is paid $250,175.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|